Magnolia Capital Advisors LLC Sells 95 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Magnolia Capital Advisors LLC lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 3.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,618 shares of the medical research company’s stock after selling 95 shares during the quarter. Magnolia Capital Advisors LLC’s holdings in IQVIA were worth $568,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Lazard Asset Management LLC increased its holdings in IQVIA by 2.9% in the 3rd quarter. Lazard Asset Management LLC now owns 2,889,263 shares of the medical research company’s stock valued at $568,460,000 after buying an additional 80,189 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its holdings in IQVIA by 3.4% in the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,325,198 shares of the medical research company’s stock valued at $457,483,000 after buying an additional 77,422 shares during the period. Wellington Management Group LLP boosted its stake in shares of IQVIA by 1.0% in the 3rd quarter. Wellington Management Group LLP now owns 1,816,266 shares of the medical research company’s stock valued at $357,350,000 after purchasing an additional 17,139 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of IQVIA by 8.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,781,283 shares of the medical research company’s stock valued at $350,467,000 after purchasing an additional 142,707 shares in the last quarter. Finally, Northern Trust Corp boosted its stake in shares of IQVIA by 1.8% in the 3rd quarter. Northern Trust Corp now owns 1,737,315 shares of the medical research company’s stock valued at $341,817,000 after purchasing an additional 31,413 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

Insider Activity

In other news, insider Ari Bousbib sold 31,678 shares of the company’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the sale, the insider now directly owns 796,752 shares of the company’s stock, valued at approximately $199,610,278.56. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, insider Ari Bousbib sold 31,678 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the completion of the sale, the insider now directly owns 796,752 shares of the company’s stock, valued at approximately $199,610,278.56. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Kevin C. Knightly sold 8,607 shares of the stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total value of $2,153,213.19. Following the sale, the insider now directly owns 5,251 shares of the company’s stock, valued at $1,313,642.67. The disclosure for this sale can be found here. Insiders sold a total of 41,285 shares of company stock valued at $10,331,003 in the last ninety days. 1.60% of the stock is owned by insiders.

IQVIA Trading Up 0.9 %

Shares of IQV stock traded up $2.22 on Wednesday, reaching $240.84. The company had a trading volume of 1,492,788 shares, compared to its average volume of 972,338. The company has a current ratio of 0.86, a quick ratio of 0.86 and a debt-to-equity ratio of 2.12. The stock has a market cap of $43.71 billion, a PE ratio of 33.04, a PEG ratio of 2.24 and a beta of 1.50. The company has a 50-day moving average of $245.50 and a 200-day moving average of $222.69. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.84 EPS for the quarter, beating analysts’ consensus estimates of $2.82 by $0.02. The company had revenue of $3.87 billion during the quarter, compared to analysts’ expectations of $3.80 billion. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. IQVIA’s revenue was up 3.5% on a year-over-year basis. During the same period in the prior year, the business posted $2.54 EPS. On average, equities analysts forecast that IQVIA Holdings Inc. will post 10.11 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on IQV shares. StockNews.com upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Friday, February 16th. Truist Financial boosted their target price on shares of IQVIA from $286.00 to $297.00 and gave the company a “buy” rating in a research note on Tuesday, February 27th. Evercore ISI boosted their target price on shares of IQVIA from $255.00 to $265.00 and gave the company a “market outperform” rating in a research note on Thursday, February 15th. Barclays upped their price target on shares of IQVIA from $260.00 to $265.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. Finally, BTIG Research assumed coverage on shares of IQVIA in a research report on Tuesday, February 13th. They set a “buy” rating and a $285.00 price target on the stock. Three research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $256.80.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.